Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.

Conclusion: In a large cohort of patients seen in routine clinical practice, risk for severe and nonsevere UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications.
Primary Funding Source: Brigham and Women's Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics.
PMID: 31357213 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - July 29, 2019 Category: Internal Medicine Authors: Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E Tags: Ann Intern Med Source Type: research